London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The statement of no SP change until March , is the worst subtle deramp. Give up. Not even worth going into why that statement is full of sh/t.
Woodstock = if the p3 data is good and expected in q4 as suggested, that should be the catalyst for a major hike in sp wouldn't you agree? The data will be with us b4 March so please explain your thoughts?
It depends on the definition of 'significant progression' to be honest.
I'd say there's at least 2 events, hopefully within the next 3 months, that'll serve as catalysts for the SP - Activ2 news and P3 results. There could of course be other things such as pre-orders at any time, or regular orders after P3 news drops.
Either way, I'm excited for what the future holds and don't think the SP will languish at this level for too much longer.
I think most of us are aware that we have a few hurdles left.
Personally I think we are looking at next March before we see any significant progression in the SP.
I am of course enthusiastic but it's quite obvious that the company is having to face obstacles.
Regards
Perhaps. But if that happens it would have to be on terms that better those of maintaining independence. If the drug performs in trial as we hope, there will be NO cheap seats in stalls for this production.
The irony is that a big pharmacy will probably buy us out.
Regards
Well put Saxon. Remdesivir is classic example of what you describe in terms of the clout of big pharma, emergency approved by the FDA in October last year; now declared bunk by the WHO. And who is behind this nigh on useless treatment that has made no doubt millions as one of the sole approved therapeutics? Gilead, with a market cap of 90 billion.
That tells you what the likes of SNG are up against, yet it is also cause for hope because eventually the science will win out here. And all the shenanigans in the world by big pharma won’t be able to hide our trial data when it finally drops.
One of the primary fears aired on this board is that we won’t arrive to the party in time. Now, gearing up for what will no doubt be another bad winter for infections, 18 months since this pandemic started, people are starting to realise that COVID, like flu, is something that will come back year after year. I’m certain we will be having the same conversation next year as we are having this year, which is the same conversation we had last year…you get my point haha.
Sure we would like news soon. And I think we will get it. But patience will be richly rewarded here I feel.
WHO delivery method was subcutaneous , which was a total waste of time , and tarred the the whole Interferon premise with the same brush .
However , putting all that aside , I'm much happier to have SNG being trialed on Synairgens own P3 trial , that has ultimately taken longer ( no short cuts ) but will give fully credible and globally recognised results .
The initial gold rush for therapies was always gonna favour BIG Pharma and existing drugs to start with , whether the evidence pointed to them or not . Many of the ones that have been approved are pretty marginal at best . But Big Pharma pull most of the strings and are always at the front of the queue , and not bothered about holding others back at the same time ( a win win for them )
Eventually , the science wins through . If you can weather the storm , and your science is good enough , it is possible to make it through .
I agree, it is good news with IFNB. The WHO intravenous trials early in the pandemic has much blame to bear for the authorities reluctance to embrace IFN.
However, we do need to keep in mind the distinction between modes of delivery: ours is inhaled for respiratory diseases whereas this was delivered as a serum. I believe intravenous or serum delivery method could be cheaper than SNG001.
So good news, but perhaps not 100% directly relevant.
Very significant findings injectable (in mice) interferon beta treatment for diabetes and severe covid 19 sufferers . I suspect inhaled interferon beta without injection would suffice very well as a treatment for these patients as demonstrated in some of our P2 trial patients with diabetes as a comorbidity .Another cohort of patients which SNG will hopefully be of great benefit .
Some findings:
https://www.thehealthsite.com/news/diabetes-and-severe-covid-19-study-suggests-interferon-as-a-potential-therapy-837567/